Investing in Cancer Immunotherapy By Dr Michelle Tempest

Dr Michelle Tempest and Dr Karen Sayal reveal in this July 2019  #LaingBuisson article promising opportunities investing in  #immunotherapy treatments

Cancer therapeutic landscape is shifting to more distinct and personalised immunotherapy treatments.

With a market expected to almost triple by 2025, several biotech firms are in early #clinicaltrials.

Opportunities arise in

- novel combinations of check-point inhibitors: engineered proteins that bind to cancer cells and indirectly signal an ‘auto-destruct’ response from the immune system

- cellular based immunotherapy that involves, for part, re-infusing specific expanded immune cells (ACT, adoptive cell transfer)

Challenges remain because of the toxicity risk and the high costs associated.

https://www.linkedin.com/feed/update/urn:li:activity:6557267033044590592/

<< Back to Publications
    Page: Loading... / Loading...    
Download PDF


About

Candesic is a leading strategy consultancy head-quartered in London, serving private operators, investors, and public sector organisations.

Privacy

Privacy Policy

News & Publications

Candesic advisor Professor Stephen Smith as a speaker at The Women's Health Technology event
Candesic advisor Professor Stephen Smith spoke at a The Women`s Health Technology GIANT Health Event in London. His participation in the panel on "How do various sectors in Women's Health overcome barriers to meaningful progress?" was moderated by Professor Dame Lesley Regan and delved into the key reasons the gender gap exists in healthcare. Professor Stephen Smith has a wealth of experience in the area among other things as a Former Professor of Obstetrics and Gynaecology at Cambridge University. Click on the link to find out more about the event.

Dr Michelle Tempest featured in the new Financial Times
Dr Michelle Tempest, Senior Partner at Candesic, featured in the Financial Times discussing the implications of increased reliance of the NHS on private providers. Private sector outsourcing has become a critical element for the NHS to deliver patient care, and while it is currently resulting in improved outcomes for patients, to address the underlying structural issues will require continued public and private investment. Click on the link to subscribe and read more.

Candesic provided commercial due diligence to Ampersand Capital Partners
Congratulations to the Ampersand Capital Partners team on their investment in Julius Clinical Research! Candesic provided commercial due diligence to Ampersand Capital Partners. Julius Clinical is a leading academic clinical CRO providing clinical trial services and real-world evidence studies to biopharma sponsors. This strategic partnership will enhance Julius Clinical capabilities in pioneering clinical research and support the development of new therapeutics on a global scale.

© Candesic 2023